HPLC Method for Evogliptin on Primesep B by SIELC Technologies
High Performance Liquid Chromatography (HPLC) Method for Analysis of Evogliptin
Evogliptin is a drug that belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors. It is used primarily for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors work by blocking the action of the enzyme DPP-4, which in turn increases the levels of incretin hormones such as GLP-1 (glucagon-like peptide-1). This increase helps to stimulate insulin release and suppress glucagon secretion, thereby helping to regulate blood sugar levels in patients with diabetes.
Evogliptin can be retained, and analyzed using a Primesep B mixed-mode stationary phase column. The analysis utilizes an isocratic method with a simple mobile phase consisting of water, acetonitrile (MeCN), and sulfuric acid as a buffer. Detection is achieved using UV at 200 nm
| Column | Primesep B, 4.6 x 150 mm, 5 µm, 100 A |
| Mobile Phase | MeCN/H2O – 15/85% |
| Buffer | H2SO4 -0.2% |
| Flow Rate | 1.0 ml/min |
| Detection | UV 300 nm |
| LOD* | 42.9 ppb |
| Class of Compounds | Dipeptidyl peptidase-4 (DPP-4) inhibitor |
| Analyzing Compounds | Evogliptin |
Application Column
Primesep B
Column Diameter: 4.6 mm
Column Length: 150 mm
Particle Size: 5 µm
Pore Size: 100 A
